Equities

ALR Technologies Inc

ALRTF:QBB

ALR Technologies Inc

Actions
  • Price (USD)0.0125
  • Today's Change-0.004 / -21.88%
  • Shares traded9.82k
  • 1 Year change-61.12%
  • Beta0.2587
Data delayed at least 15 minutes, as of Sep 20 2024 19:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ALR Technologies Inc. is a data management company. The Company is engaged in the development of a comprehensive approach to diabetes care that includes a Food and Drug Administration (FDA) cleared diabetes management system (the Diabetes Solution), which collects data directly from blood glucose meters (BGM); a patent-pending Predictive A1C algorithm to track treatment success between lab reports; and an FDA-cleared Insulin Dosing Adjustment program. The Company has developed the Diabetes Solution for human health, and the GluCurve, a modified version of the Diabetes Solution, for animal health (GluCurve) from its technology portfolio. The Company has developed its Diabetes Solution, which is a comprehensive approach to diabetes care consisting of data collection, predictive A1C, insulin dosage adjustment suggestions, performance tracking, remote monitoring and diabetes test supplies. Its subsidiaries include ALR Technologies SG Pte. Ltd. and Canada Diabetes Solution Centre Inc.

  • Revenue in USD (TTM)9.49k
  • Net income in USD-8.00m
  • Incorporated1987
  • Employees6.00
  • Location
    ALR Technologies IncSuite 300, 7400 Beaufont Springs DriveRICHMOND 23225United StatesUSA
  • Phone+1 (804) 554-3500
  • Websitehttps://www.alrt.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Telesis Bio Inc16.28m-50.12m5.48m137.00------0.3365-29.66-30.689.615.610.19473.153.40118,832.10-57.15---64.21--49.47---293.54--1.72-52.960.356--0.2697---1.14------
BioSig Technologies Inc40.00k-18.08m5.53m4.00------138.37-1.97-1.970.00410.00660.0112--1.0710,000.00-489.14-269.73-4,711.71-363.1165.00---43,760.00-24,485.73---3,115.670.00---93.71---6.52---9.58--
Reflect Scientific Inc1.73m-53.09k5.57m7.00--2.8372.303.21-0.0006-0.00060.02030.0230.71970.846317.05247,638.60-2.2011.10-2.5913.2158.1962.48-3.0610.005.68--0.00---47.09-6.99-613.46------
Venus Concept Inc69.81m-49.93m6.00m304.00--1.62--0.0859-8.38-8.3811.920.51030.7511.032.25229,634.90-53.53-32.71-82.19-44.0168.3968.16-71.28-48.501.30-2.750.9133---23.2628.3114.76---35.08--
Sharps Technology Inc0.00-8.21m6.75m3.00--0.9353-----0.4944-0.49440.000.25240.00-------75.56---100.97----------0.6446--0.00-------112.12------
Caduceus Software Systems Corp0.00-117.60k7.17m0.00---------0.0004-0.00040.00-0.00040.00-------402.19-11,090.31---------------76.88---------20,519.89------
Biotricity Inc12.24m-18.28m7.19m55.00------0.5868-1.74-1.741.18-1.272.121.678.08222,624.00-248.61-269.25----71.8958.93-117.41-258.940.106-0.6408----25.1597.8223.57------
Sigyn Therapeutics Inc0.00-3.70m7.27m5.00---------3.08-3.080.00-2.910.00----0.00-1,085.72-493.15-----------10,223.960.0247-2.09---------41.51------
Nexalin Technology Inc150.16k-5.40m7.35m6.00--3.90--48.94-0.7261-0.72610.02020.17810.04460.167911.5325,026.67-160.37---202.23--82.94---3,598.50--4.89--0.00---91.62---173.80------
Agape ATP Corp1.38m-2.45m7.39m21.00--2.29--5.36-0.6396-0.63960.35990.83660.44648.2536.6665,621.91-78.78---111.56--64.23---176.47--4.66--0.0225---22.92---24.61------
ALR Technologies Inc9.49k-8.00m7.94m6.00------837.02-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Neurometrix Inc4.38m-7.94m7.96m26.00--0.4578--1.82-5.50-5.502.918.580.21021.158.53168,600.80-38.06-23.24-40.80-27.2660.1959.17-181.03-48.8810.71--0.00---28.52-18.18-47.84--5.03--
Bioelectronics Corp1.61m-289.82k8.65m9.00------5.37-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Guided Therapeutics Inc38.00k-2.39m9.05m4.00------238.11-0.0444-0.04440.0007-0.08290.02110.03658.449,500.00-120.81-136.13----42.1129.39-5,721.05-3,666.670.0679-7.58----653.8511.4524.40------
Dror Ortho-Design Inc0.00-5.63m9.41m4.00--5.68-----0.012-0.0120.000.00340.00-------577.48-140.50-1,394.24---------118,188.00----0.00-------1,896.02------
Precipio Inc16.72m-3.83m9.90m51.00--0.8103--0.5921-2.68-2.6811.738.240.908917.1216.80327,843.10-20.82-44.98-27.94-58.6839.0828.80-22.90-118.070.590-192.590.0517--61.4639.6252.04--5.37--
Data as of Sep 20 2024. Currency figures normalised to ALR Technologies Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.